Lyon AR, López-Fernández T, Couch LS (2022) ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J 43(41):4229–4361. https://doi.org/10.1093/eurheartj/ehad196

Article  PubMed  Google Scholar 

Canonico ME, Santoro C, Avvedimento M et Al. (2022) Venous thromboembolism and cancer: A comprehensive review from pathophysiology to novel treatment biomolecules. 12(2):259. https://doi.org/10.3390/biom12020259.

Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27:4839–4847. https://doi.org/10.1200/JCO.2009.22.3271

Article  CAS  PubMed  PubMed Central  Google Scholar 

Elyamany G, Alzahrani AM, Bukhary E (2014) Cancer-associated thrombosis: an overview. Clin Med Insights Oncol 8:129–137. https://doi.org/10.4137/CMO.S1899

Article  PubMed  PubMed Central  Google Scholar 

Khorana AA, Sud R (2009) Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res 123 (Suppl 4). https://doi.org/10.1016/S0049-3848(09)70137-9.:S18-21

Khorana AA, Francis CW, Culakova E (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632–634. https://doi.org/10.1111/j.1538-7836.2007.02374.x

Article  CAS  PubMed  Google Scholar 

Lyman GH (2011) Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 117:1334–1349. https://doi.org/10.1002/cncr.25714

Article  PubMed  Google Scholar 

Chew HK, Wun T, Harvey D (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464. https://doi.org/10.1001/archinte.166.4.458

Article  PubMed  Google Scholar 

Navi BB, Reiner AS, Kamel H (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70:926–938. https://doi.org/10.1016/j.jacc.2017.06.047

Article  PubMed  PubMed Central  Google Scholar 

Cohen AT, Agnelli G, Anderson FA (2007) Venous thromboembolism (VTE) in europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98(4):756–764. https://doi.org/10.1160/TH07-03-0212

Article  CAS  PubMed  Google Scholar 

Khorana AA, Kuderer NM, Culakova E (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907. https://doi.org/10.1182/blood-2007-10-116327

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ay C, Dunkler D, Marosi C (2010) Prediction of venous thromboembolism in cancer patients. Blood 116:5377–5382. https://doi.org/10.1182/blood-2010-02-270116

Article  CAS  PubMed  Google Scholar 

Falanga A, Panova-Noeva M, Russo L (2009) Procoagulantmechanisms in tumour cells. Best Pract Res Clin Haematol 22:49–60. https://doi.org/10.1016/j.beha.2008.12.009

Article  CAS  PubMed  Google Scholar 

Casslén B, Bossmar T, Lecander I (1994) Al. Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 30:1302–1309. https://doi.org/10.1016/0959-8049(94)90178-3

Article  Google Scholar 

Chen M, Geng JG (2006) P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp 54:75–84. https://doi.org/10.1007/s00005-006-0010-6

Article  CAS  Google Scholar 

Grover SP, Hisada YM, Kasthuri RS (2021) Cancer Therapy-Associated thrombosis. Arterioscler Thromb Vasc Biol 41(4):1291–1305. https://doi.org/10.1161/ATVBAHA.120.314378

Article  CAS  PubMed  PubMed Central  Google Scholar 

Okwuosa TM, Morgans A, Rhee J-W (2021) Impact of hormonal therapies for treatment of Hormone-Dependent cancers (Breast and Prostate) on the cardiovascular system: effects and modifications: A scientific statement from the American heart association. Circ Genom Precis Med 14(3):e000082. https://doi.org/10.1161/HCG.0000000000000082

Article  CAS  PubMed  Google Scholar 

Venkatesulu BP, Mahadevan LS, Aliru ML et al (2018) Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl Sci 3(4):563–572. https://doi.org/10.1016/j.jacbts.2018.01.014

Lee AYY, Levine MN, Baker RI (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thrombo-embolism in patients with cancer. N Engl J Med 349:146–153. https://doi.org/10.1056/NEJMoa025313

Article  CAS  PubMed  Google Scholar 

Lee AYY, Kamphuisen PW, Meyer G (2015) Tinzaparin vs warfarin for treatment of acute venous thrombo-embolism in patients with active cancer: a randomized clinical trial. JAMA 314(7):677–686. https://doi.org/10.1001/jama.2015.9243

Article  CAS  PubMed  Google Scholar 

Hull RD, Pineo GF, Brant RF (2007) Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 120(1):72–82. https://doi.org/10.1016/j.amjmed.2006.03.030

Article  CAS  PubMed  Google Scholar 

Lee YJ, Park JK, Uhm JS (2016) Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy. Int J Cardiol 203:372–378. https://doi.org/10.1016/j.ijcard.2015.10.166

Article  PubMed  Google Scholar 

Agnelli G, Buller HR, Cohen A (2015) Oral Apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 13(12):2187–2191. https://doi.org/10.1111/jth.13153

Article  CAS  PubMed  Google Scholar 

Schulman S, Kearon C, Kakkar AK (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352. https://doi.org/10.1056/NEJMoa0906598

Article  CAS  PubMed  Google Scholar 

Masini M, Toma M, Spallarossa P (2023) Direct oral anticoagulants for Cancer-Associated venous thromboembolism. Curr Oncol Rep 25(9):979–987. https://doi.org/10.1007/s11912-023-01428-y

Article  PubMed  PubMed Central  Google Scholar 

Young AM, Marshall A, Thirlwall J (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017–2023. https://doi.org/10.1200/JCO.2018.78.8034

Article  CAS  PubMed  Google Scholar 

Raskob GE, Van Es N, Verhamme P (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615–624. https://doi.org/10.1056/NEJMoa1711948

Article  CAS  PubMed  Google Scholar 

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG (2020) Apixaban and Dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411–421. https://doi.org/10.1111/jth.14662

Article  CAS  PubMed  Google Scholar 

Agnelli G, Muñoz A, Franco L (2022) Apixaban and Dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost 122(5):796–807. https://doi.org/10.1055/s-0041-1735194

Article  PubMed  Google Scholar 

Schrag D, Uno H, Rosovsky R (2023) Direct oral anticoagulants vs Low-Molecular-Weight heparin and recurrent VTE in patients with cancer: A randomized clinical trial JAMA. 329(22):1924–1933. https://doi.org/10.1001/jama.2023.7843. et Al

Frere C, Farge D, Schrag D (2022) Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 15(1):69. https://doi.org/10.1186/s13045-022-01289-1

Article  PubMed  PubMed Central  Google Scholar 

Guo JP, Hlavacek P, Poretta T (2020) Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the united States. J Thromb Thrombolysis 50:386–394. https://doi.org/10.1007/s11239-019-02032-3